

# Diane M Simeone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/68131/publications.pdf>

Version: 2024-02-01

50  
papers

6,917  
citations

201674

27  
h-index

197818

49  
g-index

54  
all docs

54  
docs citations

54  
times ranked

11028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Pancreatic Cancer Stem Cells. <i>Cancer Research</i> , 2007, 67, 1030-1037.	0.9	3,017
2	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. <i>Gastroenterology</i> , 2014, 147, 1393-1404.	1.3	529
3	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	12.1	357
4	c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target. <i>Gastroenterology</i> , 2011, 141, 2218-2227.e5.	1.3	333
5	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. <i>Gut</i> , 2017, 66, 124-136.	12.1	269
6	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 5937-5945.	7.0	255
7	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	329.8	237
8	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. <i>Cancer Discovery</i> , 2018, 8, 1237-1249.	9.4	216
9	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. <i>Oncotarget</i> , 2014, 5, 12383-12397.	1.8	175
10	GM-CSF Mediates Mesenchymal-Épithelial Cross-talk in Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 886-899.	9.4	156
11	The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e91983.	2.5	138
12	CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer. <i>Pancreas</i> , 2007, 34, 436-443.	1.1	137
13	Bmi1 Enhances Tumorigenicity and Cancer Stem Cell Function in Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e55820.	2.5	94
14	High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. <i>Cell Systems</i> , 2017, 5, 295-304.e4.	6.2	88
15	Metabolic Regulation of Redox Balance in Cancer. <i>Cancers</i> , 2019, 11, 955.	3.7	80
16	A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer. <i>Translational Oncology</i> , 2014, 7, 644-649.	3.7	63
17	Opportunities and Challenges for Pancreatic Circulating Tumor Cells. <i>Gastroenterology</i> , 2016, 151, 412-426.	1.3	60
18	HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. <i>ELife</i> , 2018, 7, .	6.0	51

#	ARTICLE	IF	CITATIONS
19	The biological underpinnings of therapeutic resistance in pancreatic cancer. <i>Genes and Development</i> , 2021, 35, 940-962.	5.9	51
20	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. <i>Gut</i> , 2021, 70, 743-760.	12.1	49
21	Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. <i>Laboratory Investigation</i> , 2015, 95, 43-55.	3.7	44
22	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 18575.	3.3	38
23	An academic career in global surgery: a position paper from the Society of University Surgeons Committee on Academic Global Surgery. <i>Surgery</i> , 2018, 163, 954-960.	1.9	34
24	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1308-1319.	4.1	33
25	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2016, 34, 733-739.	2.6	31
26	Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids. <i>Oncotarget</i> , 2019, 10, 2625-2643.	1.8	31
27	Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis. <i>Nature Communications</i> , 2021, 12, 2047.	12.8	30
28	Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. <i>Carcinogenesis</i> , 2015, 36, 730-738.	2.8	29
29	Microfluidic continuum sorting of sub-populations of tumor cells via surface antibody expression levels. <i>Lab on A Chip</i> , 2017, 17, 1349-1358.	6.0	26
30	Protein Kinase A Modulates Transforming Growth Factor- $\beta$ 2 Signaling through a Direct Interaction with Smad4 Protein. <i>Journal of Biological Chemistry</i> , 2013, 288, 8737-8749.	3.4	24
31	Characterizing human pancreatic cancer precursor using quantitative tissue optical spectroscopy. <i>Biomedical Optics Express</i> , 2013, 4, 2828.	2.9	23
32	Localized Pancreatic Cancer: Multidisciplinary Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e217-e226.	3.8	23
33	ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. <i>Genes and Development</i> , 2021, 35, 218-233.	5.9	23
34	Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 1.	1.7	22
35	Islet hypertrophy following pancreatic disruption of Smad4 signaling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1305-E1316.	3.5	20
36	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. <i>Genes and Development</i> , 2019, 33, 641-655.	5.9	20

#	ARTICLE	IF	CITATIONS
37	ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. <i>Journal of Biological Chemistry</i> , 2015, 290, 27146-27157.	3.4	17
38	ATDC mediates a TP63-regulated basal cancer invasive program. <i>Oncogene</i> , 2019, 38, 3340-3354.	5.9	17
39	In vivo optical spectroscopy for improved detection of pancreatic adenocarcinoma: a feasibility study. <i>Biomedical Optics Express</i> , 2014, 5, 9.	2.9	15
40	SSAT/AGA/ASGE State of the Art Conference on Cystic Neoplasms of the Pancreas. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1475-1477.	1.7	14
41	Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. <i>Advanced Biology</i> , 2018, 2, 1800228.	3.0	13
42	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 T Pancreatic Cancer. <i>Journal of Pancreatic Cancer</i> , 2019, 5, 35-42.	0.9	10
43	Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 40.	1.7	5
44	Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform. <i>Methods in Molecular Biology</i> , 2019, 1882, 73-80.	0.9	5
45	Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. <i>Science Advances</i> , 2020, 6, .	10.3	5
46	Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. <i>Cancer</i> , 2021, 127, 2271-2278.	4.1	5
47	Proteome heterogeneity and malignancy detection in pancreatic cyst fluids. <i>Clinical and Translational Medicine</i> , 2021, 11, e506.	4.0	2
48	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 190-190.	1.6	2
49	Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 12491.	3.3	1
50	BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2676-TPS2676.	1.6	0